JP2019528061A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528061A5 JP2019528061A5 JP2019508259A JP2019508259A JP2019528061A5 JP 2019528061 A5 JP2019528061 A5 JP 2019528061A5 JP 2019508259 A JP2019508259 A JP 2019508259A JP 2019508259 A JP2019508259 A JP 2019508259A JP 2019528061 A5 JP2019528061 A5 JP 2019528061A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- amino acid
- acid sequence
- antigen recognition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021128303A JP2021184729A (ja) | 2016-08-17 | 2021-08-04 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376059P | 2016-08-17 | 2016-08-17 | |
| DE102016115246.3 | 2016-08-17 | ||
| US62/376,059 | 2016-08-17 | ||
| DE102016115246.3A DE102016115246C5 (de) | 2016-08-17 | 2016-08-17 | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| US201662376632P | 2016-08-18 | 2016-08-18 | |
| US62/376,632 | 2016-08-18 | ||
| PCT/EP2017/066630 WO2018033291A1 (en) | 2016-08-17 | 2017-07-04 | T cell receptors and immune therapy using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128303A Division JP2021184729A (ja) | 2016-08-17 | 2021-08-04 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528061A JP2019528061A (ja) | 2019-10-10 |
| JP2019528061A5 true JP2019528061A5 (enExample) | 2020-02-20 |
| JP6964351B2 JP6964351B2 (ja) | 2021-11-10 |
Family
ID=60419980
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508259A Active JP6964351B2 (ja) | 2016-08-17 | 2017-07-04 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
| JP2021128303A Pending JP2021184729A (ja) | 2016-08-17 | 2021-08-04 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128303A Pending JP2021184729A (ja) | 2016-08-17 | 2021-08-04 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10550182B2 (enExample) |
| EP (1) | EP3500593B1 (enExample) |
| JP (2) | JP6964351B2 (enExample) |
| CN (1) | CN109563149A (enExample) |
| AU (2) | AU2017312361B2 (enExample) |
| BR (1) | BR112019001922A2 (enExample) |
| CA (1) | CA3031995A1 (enExample) |
| CR (1) | CR20190095A (enExample) |
| DE (1) | DE102016115246C5 (enExample) |
| DK (1) | DK3500593T3 (enExample) |
| LT (1) | LT3500593T (enExample) |
| MA (1) | MA45976B1 (enExample) |
| MX (1) | MX395287B (enExample) |
| PE (1) | PE20190477A1 (enExample) |
| RS (1) | RS62498B1 (enExample) |
| SG (1) | SG11201900955VA (enExample) |
| TW (1) | TWI775768B (enExample) |
| WO (1) | WO2018033291A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| ZA201900664B (en) * | 2016-08-17 | 2021-09-29 | Paul Ehrlich Strasse 15 Tuebingen 72076 Germany | T cell receptors and immune therapy using the same |
| EP3595708A4 (en) * | 2017-03-15 | 2020-12-16 | Fred Hutchinson Cancer Research Center | HIGH AFFINITY MAGE-A1 SPECIFIC TCRS AND THEIR USES |
| AU2018326805B2 (en) | 2017-09-01 | 2023-11-30 | Dana-Farber Cancer Institute, Inc. | Immunogenic peptides specific to BCMA and TACI antigens for treatment of cancer |
| DE102017125888A1 (de) | 2017-11-06 | 2019-05-23 | Immatics Biotechnologies Gmbh | Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie |
| IL274505B2 (en) | 2017-11-06 | 2024-04-01 | Immatics Biotechnologies Gmbh | Novel engineered t cell receptors and immune therapy using the same |
| CN111684062A (zh) | 2018-02-09 | 2020-09-18 | 伊玛提克斯美国公司 | 制造t细胞的方法 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| MX2020014191A (es) | 2018-06-19 | 2021-03-09 | Dsm Ip Assets Bv | Variantes de enzimas lipoliticas. |
| JP7672979B2 (ja) * | 2019-01-22 | 2025-05-08 | アメリカ合衆国 | Ｇ１２ｒ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体 |
| CA3131138A1 (en) | 2019-03-06 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| ES2991645T3 (es) | 2019-06-06 | 2024-12-04 | Immatics Biotechnologies Gmbh | Clasificación con contraselección mediante péptidos de secuencia similar |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法 |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US20230227526A1 (en) * | 2020-06-09 | 2023-07-20 | Board Of Regents, The University Of Texas System | Engineered t cell receptors and methods of use |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| MX2023012899A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Polipeptidos de union a antigeno bma031 mejorados. |
| WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| AU2023262596A1 (en) | 2022-04-28 | 2024-12-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN117986350B (zh) * | 2023-02-23 | 2024-08-16 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| EP1257289A1 (en) | 2000-02-08 | 2002-11-20 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US7820401B2 (en) * | 2004-08-23 | 2010-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Collagen VI and cancer |
| EP1762575A1 (en) * | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| US8105831B2 (en) * | 2007-03-09 | 2012-01-31 | University Of Washington | Parvoviral production of HLA homozygous cells |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| US9228007B1 (en) * | 2010-03-11 | 2016-01-05 | The Regents Of The University Of California | Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| ES2745472T3 (es) * | 2013-07-15 | 2020-03-02 | The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra | Receptores de células T anti-virus del papiloma humano 16 E6 |
| WO2016011210A2 (en) * | 2014-07-15 | 2016-01-21 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| RU2739500C2 (ru) * | 2014-11-05 | 2020-12-25 | Дженентек, Инк. | Способы получения двуцепочечных белков в бактериях |
-
2016
- 2016-08-17 DE DE102016115246.3A patent/DE102016115246C5/de not_active Expired - Fee Related
-
2017
- 2017-07-04 EP EP17739220.6A patent/EP3500593B1/en active Active
- 2017-07-04 CA CA3031995A patent/CA3031995A1/en active Pending
- 2017-07-04 CN CN201780049787.2A patent/CN109563149A/zh active Pending
- 2017-07-04 CR CR20190095A patent/CR20190095A/es unknown
- 2017-07-04 SG SG11201900955VA patent/SG11201900955VA/en unknown
- 2017-07-04 JP JP2019508259A patent/JP6964351B2/ja active Active
- 2017-07-04 DK DK17739220.6T patent/DK3500593T3/da active
- 2017-07-04 PE PE2019000285A patent/PE20190477A1/es unknown
- 2017-07-04 BR BR112019001922A patent/BR112019001922A2/pt not_active IP Right Cessation
- 2017-07-04 MA MA45976A patent/MA45976B1/fr unknown
- 2017-07-04 WO PCT/EP2017/066630 patent/WO2018033291A1/en not_active Ceased
- 2017-07-04 MX MX2019001769A patent/MX395287B/es unknown
- 2017-07-04 RS RS20211327A patent/RS62498B1/sr unknown
- 2017-07-04 LT LTEPPCT/EP2017/066630T patent/LT3500593T/lt unknown
- 2017-07-04 AU AU2017312361A patent/AU2017312361B2/en not_active Ceased
- 2017-08-11 TW TW106127257A patent/TWI775768B/zh not_active IP Right Cessation
- 2017-08-15 US US15/677,651 patent/US10550182B2/en not_active Expired - Fee Related
-
2018
- 2018-07-13 US US16/035,300 patent/US10526407B2/en active Active
-
2021
- 2021-03-10 AU AU2021201518A patent/AU2021201518A1/en not_active Abandoned
- 2021-08-04 JP JP2021128303A patent/JP2021184729A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528061A5 (enExample) | ||
| JP2019088286A5 (enExample) | ||
| JP2022058932A5 (enExample) | ||
| JP2017186337A5 (enExample) | ||
| ES2565481T3 (es) | Anticuerpo anti-PlGF novedoso | |
| JP2019511222A5 (enExample) | ||
| JP2019536430A5 (enExample) | ||
| JP2023139070A5 (enExample) | ||
| JP2020500523A5 (enExample) | ||
| JP2009505676A5 (enExample) | ||
| JP2020511152A5 (enExample) | ||
| JP2010531140A5 (enExample) | ||
| JP2016505513A5 (enExample) | ||
| JP2020512019A5 (enExample) | ||
| JP2012529281A5 (enExample) | ||
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2016521692A5 (enExample) | ||
| JP2011518886A5 (enExample) | ||
| JPWO2020237227A5 (enExample) | ||
| JP2020522474A5 (enExample) | ||
| JP2011157397A5 (enExample) | ||
| JP2010110329A5 (enExample) | ||
| JP2012525149A5 (enExample) | ||
| CN102317318A (zh) | 抗cd160单克隆抗体及其用途 | |
| RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo |